Evaluating Enhanced Recovery After Surgery ERAS Protocols for Breast Cancer Patients Undergoing Breast Conserving Surgery

What this Trial Is About

Researchers are evaluating the use of Enhanced Recovery After Surgery ERAS protocols in patients undergoing breast conserving surgery BCS for breast cancer. This study aims to determine whether ERAS protocols can reduce opioid prescriptions and pain after surgery compared to standard peri-operative care. Although ERAS has been studied in oncology surgery broadly, its benefit specifically in breast conserving surgery is not well documented. The study enrolls 260 participants diagnosed with early-stage breast cancer cT1-T3 N0 undergoing lumpectomy with sentinel lymph node biopsy. Participants are randomly assigned to receive either the ERAS protocol or standard care. The ERAS protocol includes preoperative oral carbohydrate drinks, acetaminophen, and celecoxib given the day before and morning of surgery, while standard care follows routine peri-operative instructions without these interventions. Both groups may receive other medications during surgery as needed. Participants will be closely monitored for opioid prescription use within 7 days after surgery and their pain levels immediately following surgery using a numerical rating scale. Secondary measures include length of stay in the recovery room and use of anti-nausea medications. The study compares outcomes between the two groups to assess if standard care is not worse than ERAS. The total participation timeline covers the surgery day and the immediate postoperative recovery period up to 7 days.

ERAS Protocols in Breast Conserving Surgery